Opportunity Information: Apply for CDC RFA GH14 1401
Apply for CDC RFA GH14 1401
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "COOPERATIVE AGREEMENT WITH THE PAN AMERICAN HEALTH ORGANIZATION (PAHO) Protecting the Advances in Polio, Rubella and Measles Elimination Strengthening Immunization Programs in the Americas" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.185 Immunization Research, Demonstration, Public Information and EducationTraining and Clinical Skills Improvement Projects.
- This funding opportunity was created on Sep 23, 2013 and posted on Sep 23, 2013.
- Applicants must submit their applications by Dec 20, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $35,000,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- The Pan American Health Organization (PAHO) is an international public health agency with more than 100 years of experience in working to improve health and living standards of the countries of the Americas. It serves as the specialized organization for health of the Inter American System. It also serves as the Regional Office for the Americas of the World Health Organization and enjoys international recognition as part of the United Nations system. The Pan American Health Organization is the only trans national health organization in the hemisphere with a presence in each of the member countries. This and its long history of setting the standard for public health and immunizations globally makes PAHO uniquely qualified to implement the regional immunization vision and strategy.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This CDC cooperative agreement (Funding Opportunity Number CDC RFA GH14-1401) was designed to fund a single, large regional partnership with the Pan American Health Organization (PAHO) to protect and sustain the Americas progress toward polio eradication and the elimination of measles and rubella, while also strengthening broader immunization systems. The opportunity sits within CDCs global health portfolio and aligns with major US Government endorsed strategies and frameworks, including the Global Polio Eradication Initiative, the Global Measles Initiative, and the Global Immunization Vision and Strategy for 2006-2015. In practical terms, the award is intended to keep the region from backsliding on diseases that are close to elimination, while also building the long-term capacity needed to prevent outbreaks and respond quickly when threats emerge.
The core purpose of the agreement is to support the full set of building blocks that make eradication and elimination durable: strong surveillance, reliable laboratory confirmation, effective vaccination campaigns, and resilient routine immunization services. The funded work would emphasize surveillance for polio, measles, rubella, and other vaccine-preventable diseases, along with support for global and regional laboratory networks that can detect and verify cases and track transmission. This includes lab capacity for established vaccine-preventable threats as well as diseases prevented by newer vaccines, reflecting the reality that immunization programs have to evolve as new vaccines are introduced and as disease patterns change.
Another major focus is operational support for planning and implementing supplemental immunization activities, such as mass vaccination campaigns that close immunity gaps in high-risk areas or among underserved populations. Alongside campaigns, the agreement prioritizes strengthening routine immunization delivery systems so that high coverage is maintained year after year, not only during special initiatives. The opportunity also explicitly references the introduction of new vaccines and the development of related capacities in developing countries, pointing to work such as improving cold chain and logistics, training immunization staff, strengthening data systems, and supporting decision-making and rollout planning so countries can add new vaccines without weakening their existing programs.
While the headline priorities are polio, measles, and rubella, the announcement leaves room for the cooperative agreement to be used to support other global health priorities as needed, which is typical for agreements meant to support a regional public health platform. The program is tied to the Healthy People 2020 focus areas of Immunization and Infectious Diseases, signaling an emphasis on measurable public health impact, prevention, and outbreak avoidance rather than research alone.
The measurable outcomes are framed around CDC global health performance goals, especially two key targets: first, helping domestic and international partners achieve the World Health Organizations goal of global polio eradication; and second, working with global partners to reduce cumulative global measles mortality by 95 percent compared with 2000 estimates (with the baseline cited as 777,000 deaths) while maintaining elimination of endemic measles transmission across all 47 countries in the Americas. In other words, the agreement aims to both contribute to global eradication goals and protect the Americas status by preventing reestablishment of endemic transmission through strong immunization coverage, rapid detection, and swift response.
From an administrative standpoint, this was a discretionary funding opportunity using a cooperative agreement mechanism, meaning CDC would expect substantial involvement in the planning, coordination, and oversight of activities rather than simply providing funds with minimal federal engagement. The posting date was September 23, 2013, with a final closing date of December 20, 2013, and an archive date of January 19, 2014. The estimated total funding level was $35,000,000, with one expected award, and no cost sharing or matching requirement. The CFDA listing included 93.185 (Immunization Research, Demonstration, Public Information and Education, Training and Clinical Skills Improvement Projects), consistent with immunization systems strengthening and disease prevention work.
Eligibility was effectively limited to PAHO, and the announcement explains why: PAHO is the long-standing regional public health agency for the Americas, serves as WHOs Regional Office for the Americas, is part of the UN system, and uniquely maintains an operational presence across member countries. CDC justified PAHOs eligibility on the basis of its century-long leadership in immunization and public health standards in the hemisphere and its ability to implement a regional immunization vision and strategy at scale through its country footprint and convening role.
Frequently Asked Questions (FAQs)
What is the funding opportunity number for this CDC cooperative agreement?
The Funding Opportunity Number (FON) is CDC RFA GH14-1401.
What type of funding mechanism is being used?
This opportunity uses a cooperative agreement mechanism. That means CDC would have substantial involvement in planning, coordination, and oversight of the funded activities, rather than providing funding with minimal federal engagement.
Who is the intended recipient of this award?
The award was designed to fund a single, large regional partnership with the Pan American Health Organization (PAHO).
Is this opportunity open to multiple applicants or a broad pool of organizations?
No. Eligibility was effectively limited to PAHO, and the announcement describes PAHO as uniquely positioned to carry out the regional work due to its operational presence across member countries and its role as WHO's Regional Office for the Americas.
Why was PAHO the only eligible applicant?
CDC justified PAHO-only eligibility because PAHO is the long-standing regional public health agency for the Americas, part of the UN system, serves as WHO's Regional Office for the Americas, and maintains an operational presence across member countries. The announcement also cites PAHO's century-long leadership in immunization and public health standards and its ability to implement a regional strategy at scale.
How many awards were expected under this announcement?
One award was expected.
What was the estimated total funding level?
The estimated total funding level was $35,000,000.
Was cost sharing or matching required?
No. The announcement states there was no cost sharing or matching requirement.
What is the CFDA number associated with this opportunity?
The CFDA listing included 93.185: Immunization Research, Demonstration, Public Information and Education, Training and Clinical Skills Improvement Projects.
When was the opportunity posted and when did it close?
The posting date was September 23, 2013, and the final closing date was December 20, 2013.
When was the opportunity archived?
The archive date was January 19, 2014.
What is the overarching purpose of this cooperative agreement?
The core purpose is to protect and sustain progress in the Americas toward polio eradication and the elimination of measles and rubella, while also strengthening broader immunization systems to prevent backsliding and improve readiness to detect and respond to outbreaks.
Which diseases are the main focus of the funded work?
The headline priorities are polio, measles, and rubella. The work also emphasizes surveillance for other vaccine-preventable diseases and supports laboratory and immunization capacities that can adapt as new vaccines are introduced.
Does the agreement include work beyond polio, measles, and rubella?
Yes. While polio, measles, and rubella are the main priorities, the announcement notes the cooperative agreement could be used to support other global health priorities as needed, consistent with a regional public health platform.
What kinds of activities would this award support?
The funded work is intended to support the building blocks that make eradication and elimination durable, including strong surveillance, reliable laboratory confirmation, effective vaccination campaigns, and resilient routine immunization services.
What does the announcement mean by "surveillance" in this context?
Surveillance refers to activities focused on detecting and monitoring polio, measles, rubella, and other vaccine-preventable diseases, including systems that can rapidly identify potential cases and track transmission patterns.
How are laboratories and laboratory networks involved?
The opportunity supports global and regional laboratory networks that can detect and verify cases and track transmission. This includes laboratory capacity for established vaccine-preventable threats as well as diseases prevented by newer vaccines.
What role do supplemental immunization activities (SIAs) play in this program?
Operational support for planning and implementing SIAs is a major focus. SIAs include mass vaccination campaigns aimed at closing immunity gaps, especially in high-risk areas or among underserved populations.
Is routine immunization strengthening part of the scope?
Yes. The agreement prioritizes strengthening routine immunization delivery systems so high vaccination coverage can be maintained year after year, not only during special campaign periods.
Does the opportunity address introducing new vaccines?
Yes. The announcement explicitly references the introduction of new vaccines and the development of related capacities in developing countries so countries can add new vaccines without weakening existing immunization programs.
What kinds of system improvements are mentioned for new vaccine introduction?
Examples cited include improving cold chain and logistics, training immunization staff, strengthening data systems, and supporting decision-making and rollout planning.
How does this opportunity fit within CDC's broader work?
The announcement places the opportunity within CDC's global health portfolio, with emphasis on sustaining elimination/eradication gains and strengthening immunization systems across the region.
Which strategies or frameworks does this opportunity align with?
It aligns with major US Government-endorsed strategies and frameworks, including the Global Polio Eradication Initiative, the Global Measles Initiative, and the Global Immunization Vision and Strategy for 2006-2015.
Is this program more focused on research or on public health implementation?
Based on the description, the emphasis is on measurable public health impact, prevention, and outbreak avoidance through surveillance, laboratory support, immunization campaigns, and routine immunization strengthening rather than research alone.
Which Healthy People 2020 focus areas are referenced?
The opportunity is tied to Healthy People 2020 focus areas of Immunization and Infectious Diseases.
What outcomes or performance targets are highlighted?
Outcomes are framed around CDC global health performance goals, including supporting the WHO goal of global polio eradication and working with global partners to reduce cumulative global measles mortality by 95 percent compared with 2000 estimates (baseline cited as 777,000 deaths), while maintaining elimination of endemic measles transmission across all 47 countries in the Americas.
What does "maintaining elimination" mean in the context of measles in the Americas?
In this announcement, it is described as maintaining elimination of endemic measles transmission across all 47 countries in the Americas by preventing reestablishment through strong immunization coverage, rapid detection, and swift response.
What is the geographic scope of the work?
The work is described as a large regional partnership with PAHO focused on the Americas, including maintaining measles elimination across all 47 countries in the Americas.
How does this award help prevent "backsliding" on near-eliminated diseases?
The announcement describes maintaining strong surveillance, laboratory confirmation, vaccination campaigns, and robust routine immunization systems so that immunity gaps are addressed and outbreaks are detected and contained quickly.
What is the relationship between regional goals and global goals in this opportunity?
The agreement is positioned to both contribute to global eradication and mortality reduction goals and protect the Americas' progress by preventing the reestablishment of endemic transmission through strong systems and rapid response capacity.
Browse more opportunities from the same category: Health
Next opportunity: Bat Foraging Distance Survey
Previous opportunity: Center for Evaluation and Coordination of Training and Research (CECTR) in Tobacco Regulatory Science (U54)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA GH14 1401
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA GH14 1401) also looked into and applied for these:
| Funding Opportunity |
|---|
| Neurological Sciences Academic Development Award (K12) Apply for PAR 13 362 Funding Number: PAR 13 362 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Nutrition and Alcohol Related Health Outcomes (R01) Apply for PA 13 359 Funding Number: PA 13 359 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Nutrition and Alcohol Related Health Outcomes (R03) Apply for PA 13 360 Funding Number: PA 13 360 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Nutrition and Alcohol Related Health Outcomes (R21) Apply for PA 13 361 Funding Number: PA 13 361 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Rural Health Network Development (RHND) Grant Program Apply for HRSA 14 044 Funding Number: HRSA 14 044 Agency: Health Resources and Services Administration Category: Health Funding Amount: $300,000 |
| NEI Translational Research Program (TRP) on therapy for Visual Disorders (R24) Apply for PAR 13 370 Funding Number: PAR 13 370 Agency: National Institutes of Health Category: Health Funding Amount: $1,750,000 |
| Patient Centered Outcomes Research (PCOR) for Treatment Options in Uterine Fibroids Developing a Prospective Multi Center Practice based Clinical Registry (P50) Apply for RFA HS 14 006 Funding Number: RFA HS 14 006 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $4,000,000 |
| Local Capacity Initiative Apply for RFI 486 14 00001 Funding Number: RFI 486 14 00001 Agency: Thailand USAID Bangkok Category: Health Funding Amount: Case Dependent |
| Health Communication Project Apply for RFA 391 14 000001 Funding Number: RFA 391 14 000001 Agency: Pakistan USAID Islamabad Category: Health Funding Amount: $24,500,000 |
| AIDS Drug Assistance Program (ADAP) Emergency Relief Funds (ERF) Apply for HRSA 14 049 Funding Number: HRSA 14 049 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| MEASURE Evaluation Phase IV Apply for SOL OAA 14 000005 Funding Number: SOL OAA 14 000005 Agency: Agency for International Development Category: Health Funding Amount: $181,000,000 |
| NIBIB Biomedical Technology Resource Centers (P41) Apply for PAR 13 376 Funding Number: PAR 13 376 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Data Management and Coordinating Center (DMCC) for Rare Diseases Clinical Research Network (RDCRN) (U01) Apply for RFA TR 13 003 Funding Number: RFA TR 13 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Basic Research in the Pathogenesis of HIV Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R21) Apply for RFA HL 14 029 Funding Number: RFA HL 14 029 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Basic Research in the Pathogenesis of HIV Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01) Apply for RFA HL 14 024 Funding Number: RFA HL 14 024 Agency: National Institutes of Health Category: Health Funding Amount: $499,999 |
| Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions (R21) Apply for PAR 13 380 Funding Number: PAR 13 380 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions (R01) Apply for PAR 13 379 Funding Number: PAR 13 379 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Service Area Competition Additional Area (SAC AA) Marquette, Michigan Omaha, Nebraska and Hood River, Oregon Apply for HRSA 14 108 Funding Number: HRSA 14 108 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Secondary Analyses of Social and Behavioral Datasets in Aging (R03) Apply for RFA AG 14 008 Funding Number: RFA AG 14 008 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Clinical Research in the Prevention, Diagnosis, and Treatment of HIV Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01) Apply for RFA HL 14 023 Funding Number: RFA HL 14 023 Agency: National Institutes of Health Category: Health Funding Amount: $499,999 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA GH14 1401", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.